top of page



Procaine-base infusion is an effective, supportive complementary therapy for all types of cancer and many chronic diseases.


An infusion with procaine bases accelerates the deacidification of the tissue and promotes circulation in tissue that has been undersupplied for a long time and is chronically painful or inflamed.


The active substance procaine hydrochloride was already approved in 1905. In the first years, it was only used for local anaesthesia. Today, procaine-base infusions are used very successfully and effectively to support pain and inflammation therapy, revitalisation and metabolic stimulation.


In addition to its use for cancer, procaine-base infusions are also used for chronic fatigue, osteoarthritis, chronic inflammation such as rheumatism, autoimmune diseases and osteoporosis. 


Procaine has a vasodilatory and anti-inflammatory effect and neutralises free radicals (antioxidant effect). It has a balancing effect on the vegetative nervous system and serves as an anaesthetic. An important extension of the field of application of procaine is its combined application within the framework of the so-called procaine-base therapy.

A defined amount of a procaine specially approved for intravenous use is mixed with a base (sodium hydrogen carbonate, THAM) in a saline solution and administered slowly as an infusion. The simultaneous addition of alkalizing substances is carried out with the aim of prolonging the effect of procaine and improving procaine (membrane) availability by alkalizing the cell environment.

Procaine-base infusions for cancer diseases

​Tumour cells produce surplus acid, which they deposit on the outside of the cell wall - like a protective mantle. The defence cells are unable to penetrate this protection and therefore cannot reach the tumour.


Procaine-base infusions work in the body to attack the protective acid mantle of the tumour cell; the acid released can be neutralised by the alkaline infusion. In addition, the path to the tumour cell is then free and the body's own killer cells can now take direct action against the tumour cell.

bottom of page